Leap Therapeutics, Inc. – NASDAQ:LPTX
Leap Therapeutics stock price today
$0.28
-2.67
-90.51%
Financial Health
0
1
2
3
4
5
6
7
8
9
Market closed
Open in about 2 hours
Leap Therapeutics stock price monthly change
+25.53%
month
Leap Therapeutics stock price quarterly change
+25.53%
quarter
Leap Therapeutics stock price yearly change
-33.41%
year
Leap Therapeutics key metrics
Market Cap | 108.05M |
Enterprise value | N/A |
P/E | -0.65 |
EV/Sales | N/A |
EV/EBITDA | 0.37 |
Price/Sales | N/A |
Price/Book | 0.57 |
PEG ratio | 0.30 |
EPS | -2.39 |
Revenue | N/A |
EBITDA | -57.46M |
Income | -53.37M |
Revenue Q/Q | N/A |
Revenue Y/Y | N/A |
Profit margin | 0% |
Oper. margin | 0% |
Gross margin | 0% |
EBIT margin | 0% |
EBITDA margin | N/A |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeLeap Therapeutics stock price history
Leap Therapeutics stock forecast
Leap Therapeutics financial statements
| Jun 2023 | 0 | -13.39M | |
|---|---|---|---|
| Sep 2023 | 0 | -13.69M | |
| Dec 2023 | 634K | -12.46M | -1966.09% |
| Mar 2024 | 0 | -13.82M |
| Mar 2024 | 0 | -13.82M | |
|---|---|---|---|
| Sep 2025 | 9.66M | -7.37M | -76.31% |
| Oct 2025 | 9.66M | -8.77M | -90.82% |
| Dec 2025 | 11.73M | -9.11M | -77.7% |
Analysts Price target
Financials & Ratios estimates
0%
Yield TTM
| Payout ratio | 0% |
|---|
| 2019 | 1.42% |
|---|---|
| 2020 | 0.23% |
| 2021 | |
| 2022 | |
| 2023 |
| Jun 2023 | 95857000 | 11.8M | 12.31% |
|---|---|---|---|
| Sep 2023 | 83046000 | 11.03M | 13.29% |
| Dec 2023 | 72825000 | 12.68M | 17.42% |
| Mar 2024 | 57963000 | 10.59M | 18.27% |
| Jun 2023 | -10.18M | -348K | 0 |
|---|---|---|---|
| Sep 2023 | -10.48M | 0 | -1K |
| Dec 2023 | -10.38M | -100.72M | 0 |
| Mar 2024 | -15.51M | 0 | 29K |
Leap Therapeutics alternative data
Leap Therapeutics
| 12 Feb 2023 | 0 |
|---|---|
| 19 Feb 2023 | 0 |
| 26 Feb 2023 | 14 |
| 5 Mar 2023 | 21 |
| 12 Mar 2023 | 25 |
| 19 Mar 2023 | 0 |
| 26 Mar 2023 | 12 |
| 2 Apr 2023 | 0 |
| 9 Apr 2023 | 0 |
| 16 Apr 2023 | 22 |
| 23 Apr 2023 | 0 |
| 30 Apr 2023 | 17 |
| 7 May 2023 | 30 |
| 14 May 2023 | 17 |
| 21 May 2023 | 47 |
| 28 May 2023 | 0 |
| 4 Jun 2023 | 0 |
| 11 Jun 2023 | 23 |
| 18 Jun 2023 | 17 |
| 25 Jun 2023 | 0 |
Numbers represent search interest relative to the highest point on the chart for the given region and time.
A value of 100 is the peak popularity for the term.
A value of 50 means that the term is half as popular.
A score of 0 means there was not enough data for this term.
What is job openings count?
| Aug 2023 | 1 |
|---|---|
| Sep 2023 | 5 |
| Oct 2023 | 4 |
| Nov 2023 | 1 |
| Dec 2023 | 2 |
| Jan 2024 | 1 |
| Feb 2024 | 2 |
| Apr 2024 | 2 |
| May 2024 | 3 |
| Jun 2024 | 5 |
| Jul 2024 | 6 |
| Aug 2023 | 44 |
|---|---|
| Sep 2023 | 44 |
| Oct 2023 | 44 |
| Nov 2023 | 44 |
| Dec 2023 | 44 |
| Jan 2024 | 44 |
| Feb 2024 | 44 |
| Mar 2024 | 54 |
| Apr 2024 | 54 |
| May 2024 | 54 |
| Jun 2024 | 54 |
| Jul 2024 | 54 |
Leap Therapeutics other data
7.02%
-21.78%
of LPTX is owned by hedge funds
31
-28
7.95M
-24.66M
shares is hold by hedge funds
What is insider trading?
| Period | Buy | Sel |
|---|---|---|
| Sep 2021 | 6052571 | 0 |
| Transaction | Date | Insider | Security | Shares | Price per share | Total value | Source |
|---|---|---|---|---|---|---|---|
Option | MIRABELLI CHRISTOPHER director, officer: Chairman of .. | Common Stock | 5,000 | N/A | N/A | ||
Option | MIRABELLI CHRISTOPHER director, officer: Chairman of .. | Restricted Stock Units | 5,000 | N/A | N/A | ||
Option | O'MAHONY JOHN MARK officer: Chief Manufacturing Of.. | Common Stock | 5,000 | N/A | N/A | ||
Option | O'MAHONY JOHN MARK officer: Chief Manufacturing Of.. | Restricted Stock Units | 5,000 | N/A | N/A | ||
Option | SIRARD CYNTHIA officer: Chief Me.. | Common Stock | 5,000 | N/A | N/A | ||
Option | SIRARD CYNTHIA officer: Chief Me.. | Restricted Stock Units | 5,000 | N/A | N/A | ||
Option | LAWLOR AUGUSTINE officer: Chief Op.. | Common Stock | 5,000 | N/A | N/A | ||
Option | LAWLOR AUGUSTINE officer: Chief Op.. | Restricted Stock Units | 5,000 | N/A | N/A | ||
Option | ONSI DOUGLAS E director, officer.. | Common Stock | 7,500 | N/A | N/A | ||
Option | ONSI DOUGLAS E director, officer.. | Restricted Stock Units | 7,500 | N/A | N/A |
| Patent |
|---|
Application Filling date: 26 Oct 2017 Issue date: 19 Sep 2019 |
| Quarter | Transcript |
|---|---|
| Q2 2015 9 Aug 2015 | Q2 2015 Earnings Call Transcript |
| Q1 2015 12 May 2015 | Q1 2015 Earnings Call Transcript |
| Q4 2014 18 Mar 2015 | Q4 2014 Earnings Call Transcript |
| Q3 2014 4 Nov 2014 | Q3 2014 Earnings Call Transcript |
Leap Therapeutics: A Buy On Near-Term Data Catalysts In Stomach And Colon Cancer
Leap Therapeutics: 2 Catalysts With Cancer Drug DKN-01 In The 2nd Half Of 2022
Leap Therapeutics: What Prompted Prioritizing This Precision Oncology Company?
Leap Therapeutics: Another Leap Coming Up
Leap Therapeutics: All On The Line
-
What's the price of Leap Therapeutics stock today?
One share of Leap Therapeutics stock can currently be purchased for approximately $0.28.
-
When is Leap Therapeutics's next earnings date?
Unfortunately, Leap Therapeutics's (LPTX) next earnings date is currently unknown.
-
Does Leap Therapeutics pay dividends?
No, Leap Therapeutics does not pay dividends.
-
How much money does Leap Therapeutics make?
Leap Therapeutics has a market capitalization of 108.05M.
-
What is Leap Therapeutics's stock symbol?
Leap Therapeutics, Inc. is traded on the NASDAQ under the ticker symbol "LPTX".
-
What is Leap Therapeutics's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of Leap Therapeutics?
Shares of Leap Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Leap Therapeutics's key executives?
Leap Therapeutics's management team includes the following people:
- Mr. Douglas E. Onsi J.D. Chief Financial Officer, Gen. Counsel, Treasurer & Sec., Pres, Chief Executive Officer & Director(age: 56, pay: $865,240)
- Dr. Cynthia A. Sirard Chief Medical Officer(age: 55, pay: $617,040)
- Mr. Augustine J. Lawlor Chief Operating Officer(age: 68, pay: $609,510)
-
How many employees does Leap Therapeutics have?
As Jul 2024, Leap Therapeutics employs 54 workers.
-
When Leap Therapeutics went public?
Leap Therapeutics, Inc. is publicly traded company for more then 8 years since IPO on 25 Jan 2017.
-
What is Leap Therapeutics's official website?
The official website for Leap Therapeutics is leaptx.com.
-
Where are Leap Therapeutics's headquarters?
Leap Therapeutics is headquartered at 47 Thorndike Street, Cambridge, MA.
-
How can i contact Leap Therapeutics?
Leap Therapeutics's mailing address is 47 Thorndike Street, Cambridge, MA and company can be reached via phone at +61 77140360.
Leap Therapeutics company profile:
Leap Therapeutics, Inc.
leaptx.comExchange:
NASDAQ
Full time employees:
54
Industry:
Biotechnology
Sector:
Healthcare
Leap Therapeutics, Inc., a biopharmaceutical company, acquires and develops therapies for the treatment of cancer. Its lead clinical stage programs include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in multiple ongoing clinical trials for treating esophagogastric, hepatobiliary, gynecologic, and prostate cancers. Leap Therapeutics, Inc. has an option and license agreement with BeiGene, Ltd. to develop and commercialize DKN-01 in Asia (excluding Japan), Australia, and New Zealand. The company was formerly known as HealthCare Pharmaceuticals, Inc. and changed its name to Leap Therapeutics, Inc. in November 2015. Leap Therapeutics, Inc. was incorporated in 2011 and is based in Cambridge, Massachusetts.
47 Thorndike Street
Cambridge, MA 02141
Cambridge, MA 02141
CIK: 0001509745
ISIN: US52187K2006
CUSIP: 52187K101
